Results 221 to 230 of about 872,419 (247)
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
Molecular Oncology, EarlyView.PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter +2 morewiley +1 more sourceAmivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2. [PDF]
J Clin OncolTomasini P, Wang Y, Li Y, Felip E, Wu L, Cui J, Besse B, Spira AI, Neal JW, Goto K, Baik CS, Marmarelis ME, Ichihara E, Zhang Y, Lee JS, Lee SH, Yang JC, Michels S, Anastasiou Z, Curtin JC, Lyu X, Mahoney J, Demirdjian L, Meyer CS, Zhang Y, Leconte I, Lorenzini P, Knoblauch RE, Trani L, Baig M, Bauml JM, Cho BC, CHRYSALIS-2 Cohort C. +32 moreeuropepmc +1 more sourceSupplementary Figure S4 from Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
Akhilesh Mishra, Dhiraj Kumar, Kuldeep Gupta, Gabriela Lofland, Ajay Sharma, Dhanush S. Banka, Robert F. Hobbs, Robert F. Dannals, Steven P. Rowe, Edward Gabrielson, Sridhar Nimmagadda +10 moreopenalex +1 more sourceFirst-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1. [PDF]
Cardiovasc ResDesai MY, Nagueh SF, Giudicessi JR, Previs MJ, Kellner D, Pollman MJ, Varfaj F, Robertson LA, Sonicheva-Paterson N, Pushkin R, Mangal B, Tomlinson L, Harrison WG, Yamamoto L, Argast G, Lombardi LM, Ivey KN, Tingley WG. +17 moreeuropepmc +1 more source